Triple Helix Discovery Engine
Triple Helix Framework
Industry
Architects: Small & Medium Size Business (SMBs), Product Development, De-Risking, Validation, Building Niche & Emerging Markets
*Architects: Infectious Disease _ Pharmaceuticals, Biotechnology & Drugs
Alopexx (NASDAQ:ALPX)

Organization & Developments: Alopexx

Parents

*The company is developing drug candidates to treat infections.
*The firm's lead candidates are vaccine AV0328 for the treatment of pneumonia and meningococcal infections and F598 monoclonal antibody for the treatment of ICU acquired infections and prevention of post-operative abdominal infections.
2022: Alopexx To Raise ~$15m IPO With Ambition To Drive Blockbuster Sales As Prevnar's Partner_seekingalpha.com
2022: IPO Update: Alopexx Readies $15 Million U.S. IPO_seekingalpha.com
Founded to develop vaccines and antibodies for the prevention and treatment of fungal, parasitic and bacterial infections that express the target poly-N-acetyl glucosamine [PNAG].